Last reviewed · How we verify
TELMINUVO Tab. (80/5mg)
Telminuvo's mechanism of action is not well-documented, but it is believed to work by inhibiting a specific molecular target.
Telminuvo's mechanism of action is not well-documented, but it is believed to work by inhibiting a specific molecular target. Used for Phase 3 for unspecified indication.
At a glance
| Generic name | TELMINUVO Tab. (80/5mg) |
|---|---|
| Also known as | TELMINUVO Tab. |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Further research is needed to fully understand the mechanism of action of Telminuvo. It is likely that it works by interacting with a specific protein or receptor in the body.
Approved indications
- Phase 3 for unspecified indication
Common side effects
Key clinical trials
- CKD-828 (80/5mg) Pharmacokinetic Study (PHASE1)
- CKD-828 (80/5mg) Pharmacokinetic Study (PHASE1)
- Efficacy and Safety of TELMINUVO to Stage 2 Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TELMINUVO Tab. (80/5mg) CI brief — competitive landscape report
- TELMINUVO Tab. (80/5mg) updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI